Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03341468 Withdrawn - Clinical trials for Urinary Catheter-Related Discomfort

Urethral Catheter Immobilization Device to Reduce Catheter-Related Discomfort

Start date: April 1, 2018
Phase: N/A
Study type: Interventional

This is a randomized controlled study to determine the efficacy and safety of a patented urethral catheter support device designed to reduce discomfort associated with urethral catheter mobility in males. Movement of a catheter within the urethra is a source of discomfort for patients. The investigators hypothesize that this discomfort can be reduced by using an external device designed to securely fasten the catheter to the penis.

NCT ID: NCT03340233 Withdrawn - Healthy Clinical Trials

Understanding the Mechanisms of Diastolic Dysfunction

Start date: June 1, 2018
Phase: N/A
Study type: Interventional

Heart failure is a clinical syndrome marked by breathlessness, even at low levels of exertion, general fatigue, and fluid retention and is estimated to affect 5.1 million people in the United States. Heart failure with preserved ejection fraction (HFpEF) means that the heart pumps enough blood to the body, but patients still have terrible symptoms. It is estimated to account for about 50% of all heart failure cases. Experts agree that impaired filling of the heart, perhaps due to "stiffness" of the heart muscle itself, critically underlies HFpEF. There is currently no clinical technique for measuring heart muscle (myocardial) stiffness; the very definition of "myocardial stiffness" remains poorly established. Consequently, the ability to study the mechanisms that underlie HFpEF is virtually non-existent, and limited treatment options will persist without significant advances. The objective of this project is to use an Equilibrium-Material-Stability (EMS) framework that couples patient-specific clinical MRI and heart pressure data in a computational model of the heart to diagnose changes in myocardial stiffness. The central hypothesis is that the new EMS framework for understanding the mechanisms of diastolic dysfunction in HFpEF will be more sensitive and outperform currently available approaches.

NCT ID: NCT03340103 Withdrawn - Clinical trials for Antioxidant Role of the Lutein in Preterm Newborn

Early Administration of the Lutein/Zeaxanthin in Premature Newborns

Start date: October 11, 2018
Phase: N/A
Study type: Interventional

Premature birth is the most common cause of mortality, morbidity and disability. Premature infants have a higher risk of developing damage in the eyes (retinopathy of prematurity ROP), in the central nervous system (intraventricular hemorrhage IVH), in the lungs (bronchial pulmonary dysplasia BPD), in the gut (NEC) and infections. Oxidative stress has been implicated in various capacities, in the etiology of these conditions. Lutein and Zeaxanthin are powerful anti-oxidants and commonly assimilated with different foods. Lutein and Zeaxanthin are present at level of umbilical cord, in the breast milk (particularly in colostrum) and pass the placental barrier. Concerning supplementations, the lutein presents, for its specific characteristics, a high bioavailability after oral administration. In the last few years, there have been more and more studies which have shown that lutein could constitute a valid and important preventive and protective factor against certain diseases related to oxidative stress. The preparations of lutein and zeaxanthin have never pointed out in the human being (included in the term newborn) adverse or toxic effects. This spontaneous / non-commercial pilot study involves the administration of a dietary supplement containing lutein / zeaxanthin, because the healthcare structures need to identify a natural antioxidant product that can reduce the incidence of serious diseases related to oxidative stress in the perinatal period. This study aims to evaluate if the administration of lutein in watery solution will reduce the rate of free radicals in preterm infants.

NCT ID: NCT03338660 Withdrawn - Clinical trials for Platelet Dysfunction Due to Drugs

Platelet Function With Various Storage Techniques

Start date: July 15, 2018
Phase: Phase 2
Study type: Interventional

Platelet function will be tested in individuals on antiplatelet medications to determine the optimal storage methodology.

NCT ID: NCT03337997 Withdrawn - Clinical trials for Pancreatic Adenocarcinoma Resectable

A Pilot Study of IRE for Resectable Pancreatic Cancer

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

The operation to remove certain pancreatic cancers (Whipple procedure), even in 2017, remains one of the most complicated surgeries done in the abdomen. It carries a 50% chance of a complication, even in the world's largest pancreatic surgery centres. Saskatchewan is one of only two centres in Canada to have a promising new technology called Irreversible Electroporation (IRE) (NanoKnife®) available to our patients for the ablation (destruction) of cancers. IRE is different from other ablation treatments, including heat and even radiation, in that with IRE no heat is generated and there is minimal, if any, damage to nearby blood vessels, bowel, and ducts. Thus far, IRE has only been used as a "last resort" in cases where the pancreatic cancer cannot be removed with surgery, yet many patients whose tumor could likely be removed with a 'Whipple' have expressed a preference to undergo IRE instead of the Whipple procedure. Our main research questions are: In comparison to Whipple procedure, is IRE an effective treatment of pancreatic cancer, and are complications reduced? Is IRE cost-effective? Based on the cases we have done and published series of IRE for stage III pancreatic cancer, we believe that IRE will be effective and safe in treating lesser stage (I and II) tumors in our proposed study. This will be a pilot study of 12-15 patients, and all recruited patients will receive the IRE treatment and then be followed for up to 5 years for quality of life, recurrence, survival, and cost.

NCT ID: NCT03336021 Withdrawn - Clinical trials for Poverty, Low Income, Food Insecurity, Undernutrition

Impact Evaluation of Agribusiness Support and Nutrition Services Projects in Upper Egypt

Start date: November 1, 2017
Phase: N/A
Study type: Interventional

This project seeks to evaluate the impact of two USAID-funded projects that are implemented in rural Upper Egypt. The first project is the Feed the Future Egypt, Food-Security and Agribusiness Support (FAS) project; the second project is the Improving Maternal, Child Health, and Nutrition Services (IMCHN) project. The specific study objectives are (1) to estimate the impact of FAS interventions on project outcome indicators—especially on household income (measured by total household expenditure), household food security, and maternal and child nutrition—among farm households; (2) to estimate the effects of IMCHN interventions on maternal and child health and nutrition knowledge among community health workers (CHWs) and among farm households; and (3) to analytically explore potential synergistic effects of FAS and IMCHN interventions on maternal and child nutrition among farm households being exposed to both projects.

NCT ID: NCT03335020 Withdrawn - Clinical trials for Atherosclerosis of Artery

Using Ultrasonography, Shear Wave Elastography, Strain Imaging, and 3-D Volume Ultrasonography on Cardiovascular Disease

Start date: April 1, 2018
Phase: Phase 1
Study type: Interventional

The researchers are trying to see whether contrast-enhanced ultrasonography, shear wave elastography, strain imaging, and 3-D volume ultrasonography improves arterial wall visualization and identifies arterial elastic properties among individuals with fibromuscular dysplasia (FMD), atherosclerosis, personal history of spontaneous coronary artery dissections (SCAD), or personal history of segmental arterial mediolysis (SAM) that may be different compared to those without the aforementioned conditions.

NCT ID: NCT03332043 Withdrawn - Clinical trials for Cardiovascular Diseases

HIRREM for Pre-Hypertension

Start date: March 2018
Phase: N/A
Study type: Interventional

This randomized, controlled clinical pilot trial will evaluate the effects associated with in-office use of closed-loop, acoustic stimulation neurotechnology (High-resolution, relational, resonance-based, electroencephalic mirroring; HIRREM), compared with acoustic stimulation not linked to brainwaves (ambient nature sounds), for participants with pre-hypertension. Data collection will occur at baseline, and at intervals after completion of the intervention. Outcomes include blood pressure, measures of autonomic cardiovascular regulation, behavioral symptom outcomes, quality of life, alcohol use, and functional performance measures. The primary outcome will be change in blood pressure from baseline to 4-6 weeks after intervention.

NCT ID: NCT03332030 Withdrawn - Clinical trials for Neurofibromatosis Type 1

Stem Cells in NF1 Patients With Tumors of the Central Nervous System

Start date: November 27, 2015
Phase:
Study type: Observational

Objectives 1. Establish an induced pluripotent stem cell (iPSC) bank for phenotypically well-characterized patients with NF1. 2. Develop isogenic NF1 wild-type (NF1+/+), NF1 heterozygous (NF1+/-) and NF1 homozygous (NF1-/-) iPSC lines from individual patients using CRISPR/CAS9 technology. 3. Differentiate and characterize disease-relevant brain cells such as excitatory and inhibitory neurons, astrocytes and oligodendrocytes from patient-specific iPSC lines. 4. Screen and identify the drug(s) that can reverse or alleviate the disease phenotypes.

NCT ID: NCT03328936 Withdrawn - Clinical trials for Recurrent Plasma Cell Myeloma

Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant

Start date: September 1, 2018
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies the side effects and how well melphalan hydrochloride works in treating patients with multiple myeloma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as melphalan hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.